CRISPR/Cas9 for overcoming drug resistance in solid tumors

Ali Saber, Bin Liu, Pirooz Ebrahimi, Hidde J. Haisma*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)
78 Downloads (Pure)

Abstract

Objectives: In this review, we focus on the application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated nuclease 9 (Cas9), as a powerful genome editing system, in the identification of resistance mechanisms and in overcoming drug resistance in the most frequent solid tumors. Data acquisition: Data were collected by conducting systematic searching of scientific English literature using specific keywords such as “cancer”, “CRISPR” and related combinations. Results: The review findings revealed the importance of CRISPR/Cas9 system in understanding drug resistance mechanisms and identification of resistance-related genes such as PBRM1, SLFN11 and ATPE1 in different cancers. We also provided an overview of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as paclitaxel and sorafenib. Conclusion: The data suggest CRISPR/Cas9 system as a useful tool in elucidating the molecular basis of drug resistance and improving clinical outcomes. [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)295-304
Number of pages10
JournalDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Volume28
Issue number1
Early online date21-Jan-2019
DOIs
Publication statusPublished - Jun-2020

Keywords

  • Solid tumor
  • CRISPR
  • Cas9
  • Targeted therapy
  • Drug resistance
  • Drug response
  • Clinical outcome
  • CELL LUNG-CANCER
  • DISTANT METASTASIS
  • SENSITIVITY
  • PROMOTES
  • GROWTH
  • GLIOBLASTOMA
  • INHIBITORS
  • MUTATION
  • IDENTIFICATION
  • CRISPR-CAS9

Cite this